Loading
Every dated change on the records linked to Medullary thyroid cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Medullary thyroid cancer (Cometriq)
Cabozantinib lengthened progression-free survival compared with placebo in progressive medullary thyroid cancer; approved in November 2012.
Vandetanib prolonged progression-free survival over placebo in advanced medullary thyroid cancer; approved in April 2011 as the first drug for the disease.
A milestone in how this cancer is treated.